163 related articles for article (PubMed ID: 34128760)
1. Recent updates on Wnt signaling modulators: a patent review (2014-2020).
Goswami VG; Patel BD
Expert Opin Ther Pat; 2021 Nov; 31(11):1009-1043. PubMed ID: 34128760
[No Abstract] [Full Text] [Related]
2. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.
Serafino A; Sferrazza G; Colini Baldeschi A; Nicotera G; Andreola F; Pittaluga E; Pierimarchi P
Expert Opin Drug Discov; 2017 Feb; 12(2):169-186. PubMed ID: 27960558
[TBL] [Abstract][Full Text] [Related]
3. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
Shah K; Panchal S; Patel B
Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
[TBL] [Abstract][Full Text] [Related]
4. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
5. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
6. Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.
Liu Z; Wang P; Wold EA; Song Q; Zhao C; Wang C; Zhou J
J Med Chem; 2021 Apr; 64(8):4257-4288. PubMed ID: 33822624
[TBL] [Abstract][Full Text] [Related]
7. Wnt signaling as potential therapeutic target in lung cancer.
Yang J; Chen J; He J; Li J; Shi J; Cho WC; Liu X
Expert Opin Ther Targets; 2016 Aug; 20(8):999-1015. PubMed ID: 26882052
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.
Le PN; McDermott JD; Jimeno A
Pharmacol Ther; 2015 Feb; 146():1-11. PubMed ID: 25172549
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: recent approaches and current challenges.
Serafino A; Giovannini D; Rossi S; Cozzolino M
Expert Opin Drug Discov; 2020 Jul; 15(7):803-822. PubMed ID: 32281421
[TBL] [Abstract][Full Text] [Related]
12. The Wnt pathway: emerging anticancer strategies.
Gupta A; Verma A; Mishra AK; Wadhwa G; Sharma SK; Jain CK
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):138-47. PubMed ID: 23432158
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Wnt signaling pathway in colorectal cancer.
Sawa M; Masuda M; Yamada T
Expert Opin Ther Targets; 2016; 20(4):419-29. PubMed ID: 26439805
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Wnt/β-catenin signaling pathway in human cancers.
Yao H; Ashihara E; Maekawa T
Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
[TBL] [Abstract][Full Text] [Related]
15. Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine.
Dodge ME; Moon J; Tuladhar R; Lu J; Jacob LS; Zhang LS; Shi H; Wang X; Moro E; Mongera A; Argenton F; Karner CM; Carroll TJ; Chen C; Amatruda JF; Lum L
J Biol Chem; 2012 Jun; 287(27):23246-54. PubMed ID: 22593577
[TBL] [Abstract][Full Text] [Related]
16. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
Ma H; Chen Q; Zhu F; Zheng J; Li J; Zhang H; Chen S; Xing H; Luo L; Zheng LT; He S; Zhang X
Eur J Med Chem; 2018 Apr; 149():110-121. PubMed ID: 29499483
[TBL] [Abstract][Full Text] [Related]
18. Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators.
Mazur M; Bujak A; Matloka M; Janowska S; Gunerka P; Bojarski L; Stanczak A; Klejman A; Bednarek A; Lamparska-Przybysz M; Wieczorek M
Anal Biochem; 2015 Apr; 475():56-67. PubMed ID: 25659657
[TBL] [Abstract][Full Text] [Related]
19. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
[TBL] [Abstract][Full Text] [Related]
20. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
